Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid Antagonism Enhances Marijuana's Effects in Heavy Marijuana Smokers
NCT00403117Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Dec 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in cannabis use disorder (CUD) (10 arms), sponsored by New York State Psychiatric Institute. Primary endpoints: Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose at 6 weeks, Change in Mean Psychomotor Task Performance as a Function of Marijuana Strength and Naltrexone Dose at 6 weeks and 1 more. Started Dec 2006; status: completed.
02
Drugs
naltrexone
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT00403117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00403117.